Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 819-827

  Min, Sang Hee ^a   Goldman, I David ^a   Zhao, Rongbao ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Caffeine; Mesothelioma; Pemetrexed; Theobromine

Indexed keywords

ATM PROTEIN; CAFFEINE; CHECKPOINT KINASE 1; PEMETREXED; THEOBROMINE;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL KILLING; CELL SURVIVAL; CHEMOSENSITIZATION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CAFFEINE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; THEOBROMINE; TUMOR SUPPRESSOR PROTEINS;

EID: 39749101621     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0539-z     Document Type: Article

References (37)

1. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123
2. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID (2005) Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 11:1294-1301
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
5. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59:4375-4382
6. Hall-Jackson CA, Cross DA, Morrice N, Smythe C (1999) ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18:6707-6713
7. Blasina A, Price BD, Turenne GA, McGowan CH (1999) Caffeine inhibits the checkpoint kinase ATM. Curr Biol 9:1135-1138
8. Zhou BB, Chaturvedi P, Spring K, Scott SP, Johanson RA, Mishra R, Mattern MR, Winkler JD, Khanna KK (2000) Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 275:10342-10348
9. Asaad NA, Zeng ZC, Guan J, Thacker J, Iliakis G (2000) Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 19:5788-5800
10. Wang H, Boecker W, Wang H, Wang X, Guan J, Thompson LH, Nickoloff JA, Iliakis G (2004) Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. Oncogene 23:824-834
11. Golding SE, Rosenberg E, Khalil A, McEwen A, Holmes M, Neill S, Povirk LF, Valerie K (2004) Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem 279:15402-15410
12. Byfield JE, Murnane J, Ward JF, Calabro-Jones P, Lynch M, Kulhanian F (1981) Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br J Cancer 43:669-683
13. Fingert HJ, Chang JD, Pardee AB (1986) Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 46:2463-2467
14. Janss AJ, Levow C, Bernhard EJ, Muschel RJ, McKenna WG, Sutton L, Phillips PC (1998) Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines. Exp Cell Res 243:29-38
15. Takahashi M, Yanoma S, Yamamoto Y, Rino Y, Amano T, Imada T (1998) Combined effect of CDDP and caffeine against human gastric cell line in vivo. Anticancer Res 18:4399-4401
16. Boike GM, Petru E, Sevin BU, Averette HE, Chou TC, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras J (1990) Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol 38:315-322
17. Deplanque G, Ceraline J, Lapouge G, Dufour P, Bergerat JP, Klein-Soyer C (2004) Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation. Biochem Biophys Res Commun 314:1100-1106
18. Traganos F, Kapuscinski J, Darzynkiewicz Z (1991) Caffeine modulates the effects of DNA-intercalating drugs in vitro: a flow cytometric and spectrophotometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and the doxorubicin analogue AD198. Cancer Res 51:3682-3689
19. Traganos F, Kapuscinski J, Gong J, Ardelt B, Darzynkiewicz RJ, Darzynkiewicz Z (1993) Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Cancer Res 53:4613-4618
20. Cohen MH, Schoenfeld D, Wolter J (1980) Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. Cancer Treat Rep 64:151-153
21. Dougherty JB, Kelsen D, Kemeny N, Magill G, Botet J, Niedzwiecki D (1989) Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. J Natl Cancer Inst 81:1735-1738
22. Al Sukhun S, Zalupski MM, Ben Josef E, Vaitkevicius VK, Philip PA, Soulen R, Weaver D, Adsay V, Heilbrun LK, Levin K, Forman JD, Shields AF (2003) Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. Am J Clin Oncol 26:543-549
23. Ahmed S, Vaitkevicius VK, Zalupski MM, Du W, Arlauskas P, Gordon C, Kellogg C, Shields AF (2000) Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study. Am J Clin Oncol 23:420-424
24. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, Yamamoto N (1998) Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18:657-666
25. Tsuchiya H, Tomita K, Yamamoto N, Mori Y, Asada N (1998) Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. Anticancer Res 18:3651-3656
26. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K (2005) Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 25:2399-2405
27. Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57:401-411
28. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
29. Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA, Korbonits M, Korbonits D, Barnes PJ (2005) Theobromine inhibits sensory nerve activation and cough. FASEB J 19:231-233
30. Kawahara M, Kagiyama H, Kanazawa Y, Tsuchiya H, Tomita K, Yokogawa K, Miyamoto K (2004) Rapid determination method of caffeine and application to monitoring of caffeine-assisted chemotherapy. Biopharm Drug Dispos 25:61-67
31. Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, Axten CW, Nolan RP, Aaronson SA (2005) Evidence against a role for SV40 in human mesothelioma. Cancer Res 65:2602-2609
32. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, Tang W, Friend S (1995) Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55:1643-1648
33. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, Groudine M (1995) Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res 55:1639-1642
34. Yao SL, Akhtar AJ, McKenna KA, Bedi GC, Sidransky D, Mabry M, Ravi R, Collector MI, Jones RJ, Sharkis SJ, Fuchs EJ, Bedi A (1996) Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 2:1140-1143
35. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR (2001) The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 7:2114-2123
36. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG (2002) The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62:2644-2649
37. Cortez D (2003) Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 278:37139-37145